SCHEMBL3533748

SCHEMBL3533748

Cc1ccc(NC(=O)c2cc(-n3ccnc3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 15/20 0.70
PDGFRA P16234 12/20 0.70
BCR P11274 8/20 0.70
PDGFRB P09619 7/20 0.70
KIT P10721 7/20 0.70
LDLR P01130 2/20 0.70
PCSK9 Q8NBP7 2/20 0.70
EPHB6 O15197 1/20 0.70
CA12 O43570 1/20 0.70
CACNA1F O60840 1/20 0.70
SLC22A3 O75751 1/20 0.70
STK10 O94804 1/20 0.70
CA1 P00915 1/20 0.70
CA2 P00918 1/20 0.70
RAF1 P04049 1/20 0.70
LCK P06239 1/20 0.70
FYN P06241 1/20 0.70
CSF1R P07333 1/20 0.70
CA3 P07451 1/20 0.70
YES1 P07947 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31017569 0.92 ABL1 (0.83) ABL1PDGFRABCRPDGFRBKIT
SCHEMBL16626833 0.92 ABL1 (0.83) ABL1PDGFRABCRPDGFRBKIT
SCHEMBL11925411 0.91 ABL1 (0.69) ABL1PDGFRABCRPDGFRBKIT
SCHEMBL5222415 0.91 ABL1 (0.84) ABL1PDGFRABCRPDGFRBKIT
Hydrochloric Acid SCHEMBL28636000 0.91 ABL1 (0.82) ABL1PDGFRABCRPDGFRBKIT
SCHEMBL29441265 0.90 ABL1 (0.77) ABL1PDGFRABCRPDGFRBKIT
SCHEMBL868006 0.90 ABL1 (0.77) ABL1PDGFRABCRPDGFRBKIT
Hydrochloric Acid SCHEMBL868161 0.89 ABL1 (0.76) ABL1PDGFRABCRPDGFRBKIT
SCHEMBL3530974 0.89 TEK (0.69) ABL1PDGFRABCRPDGFRBKIT
SCHEMBL12744294 0.88 ABL1 (0.75) ABL1PDGFRABCRPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655669-B2 Pyrimidineamide derivatives and the use thereof NOVARTIS AG (CH) 2010-02-02 US disclosed
EP-1546127-B1 NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF NOVARTIS AG (CH) 2007-08-08 EP disclosed
US-20060142577-A1 Novel pyrimidineamide derivatives and the use thereof NOVARTIS AG (CH) 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142577-A1 Novel pyrimidineamide derivatives and the use thereof TYMP, NME2, DPYD ABL1 197/4885PDGFRA 366/4885BCR 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.